vs
Side-by-side financial comparison of SuperCom Ltd (SPCB) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
SuperCom Ltd is the larger business by last-quarter revenue ($14.2M vs $9.3M, roughly 1.5× STRATA Skin Sciences, Inc.). SuperCom Ltd runs the higher net margin — 37.5% vs 0.6%, a 36.9% gap on every dollar of revenue. On growth, SuperCom Ltd posted the faster year-over-year revenue change (-1.5% vs -3.0%). STRATA Skin Sciences, Inc. produced more free cash flow last quarter ($-551.0K vs $-3.6M).
Super.com is a technology company headquartered in San Francisco and co-founded by Hussein Fazal and Henry Shi. The company provides financial services, including reward programs and travel bookings.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
SPCB vs SSKN — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.2M | $9.3M |
| Net Profit | $5.3M | $58.0K |
| Gross Margin | 61.2% | 61.8% |
| Operating Margin | 16.3% | 5.3% |
| Net Margin | 37.5% | 0.6% |
| Revenue YoY | -1.5% | -3.0% |
| Net Profit YoY | 79.5% | 101.3% |
| EPS (diluted) | $1.32 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $9.3M | ||
| Q3 25 | — | $6.9M | ||
| Q2 25 | $14.2M | $7.7M | ||
| Q1 25 | — | $6.8M | ||
| Q4 24 | — | $9.6M | ||
| Q3 24 | — | $8.8M | ||
| Q2 24 | $14.4M | $8.4M | ||
| Q1 24 | — | $6.8M |
| Q4 25 | — | $58.0K | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | $5.3M | $-2.6M | ||
| Q1 25 | — | $-2.1M | ||
| Q4 24 | — | $-4.6M | ||
| Q3 24 | — | $-2.1M | ||
| Q2 24 | $3.0M | $-91.0K | ||
| Q1 24 | — | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | 61.2% | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | 52.3% | 59.0% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | -16.9% | ||
| Q2 25 | 16.3% | -30.1% | ||
| Q1 25 | — | -25.0% | ||
| Q4 24 | — | -44.7% | ||
| Q3 24 | — | -18.2% | ||
| Q2 24 | 7.7% | -5.7% | ||
| Q1 24 | — | -42.7% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | -23.4% | ||
| Q2 25 | 37.5% | -33.6% | ||
| Q1 25 | — | -31.2% | ||
| Q4 24 | — | -47.6% | ||
| Q3 24 | — | -23.6% | ||
| Q2 24 | 20.6% | -1.1% | ||
| Q1 24 | — | -49.8% |
| Q4 25 | — | $0.14 | ||
| Q3 25 | — | $-0.36 | ||
| Q2 25 | $1.32 | $-0.62 | ||
| Q1 25 | — | $-0.51 | ||
| Q4 24 | — | $-2.01 | ||
| Q3 24 | — | $-0.51 | ||
| Q2 24 | $1.19 | $-0.03 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.0M | $7.9M |
| Total DebtLower is stronger | $23.6M | $15.3M |
| Stockholders' EquityBook value | $37.3M | $2.9M |
| Total Assets | $65.5M | $30.5M |
| Debt / EquityLower = less leverage | 0.63× | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.9M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | $15.0M | $6.0M | ||
| Q1 25 | — | $6.5M | ||
| Q4 24 | — | $7.3M | ||
| Q3 24 | — | $7.1M | ||
| Q2 24 | $5.7M | $5.5M | ||
| Q1 24 | — | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | $23.6M | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | $29.2M | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | $1.3M | ||
| Q2 25 | $37.3M | $532.0K | ||
| Q1 25 | — | $3.0M | ||
| Q4 24 | — | $5.0M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | $13.8M | $9.5M | ||
| Q1 24 | — | $9.4M |
| Q4 25 | — | $30.5M | ||
| Q3 25 | — | $30.7M | ||
| Q2 25 | $65.5M | $29.5M | ||
| Q1 25 | — | $33.0M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | $49.6M | $38.8M | ||
| Q1 24 | — | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | 0.63× | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | 2.11× | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.2M | $-239.0K |
| Free Cash FlowOCF − Capex | $-3.6M | $-551.0K |
| FCF MarginFCF / Revenue | -25.3% | -5.9% |
| Capex IntensityCapex / Revenue | 10.0% | 3.4% |
| Cash ConversionOCF / Net Profit | -0.41× | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $-14.0M | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-239.0K | ||
| Q3 25 | — | $-64.0K | ||
| Q2 25 | $-2.2M | $-1.9M | ||
| Q1 25 | — | $-550.0K | ||
| Q4 24 | — | $703.0K | ||
| Q3 24 | — | $-302.0K | ||
| Q2 24 | $-950.0K | $591.0K | ||
| Q1 24 | — | $-804.0K |
| Q4 25 | — | $-551.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | $-3.6M | $-2.0M | ||
| Q1 25 | — | $-749.0K | ||
| Q4 24 | — | $199.0K | ||
| Q3 24 | — | $-364.0K | ||
| Q2 24 | $-1.6M | $246.0K | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | -5.9% | ||
| Q3 25 | — | -15.6% | ||
| Q2 25 | -25.3% | -26.1% | ||
| Q1 25 | — | -11.0% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | -4.1% | ||
| Q2 24 | -10.8% | 2.9% | ||
| Q1 24 | — | -22.6% |
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | 10.0% | 0.8% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | 5.3% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | 4.2% | 4.1% | ||
| Q1 24 | — | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.41× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.32× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SPCB
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
